Adastra Holdings (CSE:XTRX, FRA:D2EA) Ltd, formerly known as Phyto Extractions Inc, has successfully created a CBD isolate, allowing for the development and commercialization of recreational, medical, and cosmetic products.
The CBD isolate was intentionally designed for patients and consumers seeking the benefits of CBD without experiencing the effects of THC.
Adastra’s isolate is described as a 99% pure CBD crystalline isolate nearly free of THC, thus eliminating the psychoactive effects. Available in a crystalline powder, CBD isolate can be formulated into a wide range of products, including tinctures, oils, topicals, vapes, and capsules.
READ: Adastra Holdings completes acquisition of Phyto Extractions
Jean-Paul Lim MD, FRCPC and Medical Director at PerceiveMD, a wholly-owned subsidiary that Adastra acquired in August 2021, offered the following commentary in a statement regarding the CBD isolate.
"Significant research clearly shows that CBD can help reduce pain, anxiety, and inflammation while protecting the skin," said Lim. "Furthermore, CBD is highly tolerable, does not produce euphoria, and has a low risk for adverse effects.”
With that in mind, Adastra’s isolate products are expected to provide the meaningful benefits of CBD without the psychoactive effects, addressing a significant and growing patient need.
“Additionally, CBD derived from hemp enables people who are unable to tolerate THC due to sensitivities, or who have certain mental health issues such as bipolar, schizophrenia, severe depression or anxiety, to enjoy the benefits of CBD," Lim added.
Adastra plans to distribute its line of CBD isolate products through a variety of channels. The August acquisition of PerceiveMD gives Adastra access to over 4,500 patients seeking holistic remedies.
The manufacturer and supplier of innovative ethnobotanical and cannabis science products also plans to pursue immediate distribution through the Ageless Living clinics in British Columbia and Alberta, as well as third-party clinics throughout Canada.
"Adastra has developed cryo-ethanol extraction processes that are extremely scalable for extracting cannabinoids from hemp, which enables compound isolation,” said Donald Dinsmore, Adastra's Chief Operating Officer.
The BC-based firm also operates Adastra Labs, a 13,500 square foot agricultural-scale Health Canada licensed facility focused on extraction, distillation, and manufacturing of cannabis-derived products.
“CBD isolate is an attractive ingredient for a variety of medical and recreational products – it is very pure with greater than 99% CBD and can be derived from hemp, a very low-cost raw material,” added Dinsmore. “With the successful creation of a CBD isolate, we are now developing a range of medical and consumer-focused products. These products leverage our recent acquisition of PerceiveMD.”
The company is now in the process of obtaining a medical sales license which it anticipates receiving before the end of the year. Using the license Adastra will prescribe medical and related products through PerceiveMD patient centers and other channels.
Contact the writer at georgia@proactiveinvestors.com
Follow her on Twitter @MissInformd